DRSLTR 1 filename1.htm DRSLTR

 

LOGO

 

December 30, 2020

     53rd at Third
     885 Third Avenue
     New York, New York 10022-4834
     Tel: +1.212.906.1200 Fax: +1.212.751.4864
    

www.lw.com

 

     FIRM / AFFILIATE OFFICES
     Beijing    Moscow
     Boston    Munich
     Brussels    New York
     Century City    Orange County
     Chicago    Paris
     Dubai    Riyadh
     Düsseldorf    San Diego
     Frankfurt    San Francisco
     Hamburg    Seoul
     Hong Kong    Shanghai
     Houston    Silicon Valley
     London    Singapore
     Los Angeles    Tokyo
     Madrid    Washington, D.C.
     Milan   

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-6010

 

Attention:    Christie Wong
   Angela Connell
   Laura Crotty
   Tim Buchmiller
Re:    Bioventus Inc.
   Amendment No. 1 to Draft Registration Statement on Form S-1
   Submitted November 10, 2020
   CIK No. 0001665988

Ladies and Gentlemen:

On behalf of Bioventus Inc. (the “Company”), we are transmitting this letter in response to the comment received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter dated November 18, 2020 with respect to the above-referenced registration statement (as amended from time to time, the “Registration Statement”) of the Company submitted on a confidential basis with the Commission on November 10, 2020. We are submitting this letter via EDGAR in response to the Staff’s comment.

The bold and numbered paragraph below corresponds to the numbered paragraph in the Staff’s letter and is followed by the Company’s response. Unless otherwise indicated, capitalized terms used herein have the meaning assigned to them in the Registration Statement.


December 30, 2020

Page 2

 

LOGO

 

Intellectual Property

Patents, page 165

 

  1.

We note your response to our prior comment 11. Please further revise the narrative and related table to detail the type of patent protection obtained or sought and the expected expiration year of each patent application on an individual basis.

Response: In response to the Staff’s comment, the Company proposes to revise pages 165-166 of the prospectus included in the Registration Statement as shown on Exhibit A attached hereto.

* * *

We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (714) 755-8008 with any questions or comments regarding this correspondence.

 

Very truly yours,

/s/ Wesley Holmes

Wesley Holmes

of LATHAM & WATKINS LLP

 

cc:

(via email)

    

Kenneth M. Reali, Chief Executive Officer, Bioventus Inc.

    

Gregory O. Anglum, Senior Vice President and Chief Financial Officer, Bioventus Inc.

    

Anthony D’Adamio, Senior Vice President and General Counsel, Bioventus Inc.

    

Charles K. Ruck, Esq., Latham & Watkins LLP

    

Wesley C. Holmes, Esq., Latham & Watkins LLP

    

Katherine A. Lovejoy, Esq., Latham & Watkins LLP


Exhibit A

Patents

We own numerous patents and/or patent applications which relate to our material products, including patents and/or patent applications with respect to our Exogen system, OsteoAMP and MOTYS. Although in the aggregate our intellectual property is of material importance to our business, we do not believe that any single patent is of material importance to our product portfolio. As of November 613, 2020, we owned sixfour issued U.S. patents and threetwo pending U.S. patent applications relating to our material products. We also owned 14nine issued foreign patents and 1411 pending foreign patent applications directed to our material products. Our patents and patent applications directed to our material products are summarized below.

We own fiveowned three issued U.S. patents and one issued foreign patent in Australia directed to our Exogen system. TheseThe U.S. patents are expected to expire in 2026 and 2027, respectivelybetween 2027 and 2029, and the foreign patent is expected to expire in 2025.

We ownowned one issued U.S. patent, twoone pending U.S. patent applications, 13eight issued foreign patents, and 14ten pending foreign patent applications directed to our OsteoAMP product, including foreign patents and patent applications in Europe, Asia, Canada and Australia. The issued U.S. patent is expected to expire in 20362029 . The issued foreign patents are expected to expire betweenin 2029 and 2039. The pending patent applications, if issued, are expected to expire betweenin 2029 and 2039, without accounting for potential patent term extensions and adjustments.

We also own one pending U.S. patent application and one pending Patent Cooperation Treaty application directed to MOTYS. This patent application, if issued, isPatents issuing from these applications, if any, are expected to expire in 20392040 , without accounting for potential patent term extensions and adjustments. Our patents and pending patent applications directed to our material products are detailed in the table below.

 

Country

  

Application

Number

  

Filing Date

  

Patent Number

   Application
Status
   Expected
Expiration
Date

 

  

Description

 

   Product
AU    2010328427    03-Dec-2010    2010328427    Issued          Osteoamp
AU    2014218483    01-Sep-2014    2014218483    Issued          Osteoamp
BR    1120120142631    03-Dec-2010    PI 1120120142631    Issued          Osteoamp
BR    BR122018072218-5    29-Oct-2018    BR122018072218-5    Issued          Osteoamp
CN    201080063724.0    03-Dec-2010    2010800637240    Issued          Osteoamp
EP    18186867.0    01-Aug-2018    -    Pending          Osteoamp
JP    2018-018708    05-Feb-2018    -    Pending          Osteoamp
JP    2019-070747    02-Apr-2019    -    Pending          Osteoamp
US    15/252737    31-Aug-2016       Pending          Osteoamp
                    
AU    2009324417   

13-Dec-

2009Dec. 13,

2009

   2009324417    Issued    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

AU    2014259553   

07-Nov-

2014Nov. 14,

2014

   2014259553    Issued    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

AU    2016213839   

11-Aug-

2016Aug. 11,

2016

   2016213839    Issued    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

CA    2746668   

13-Dec-

2009Dec. 13,

2009

   2746668    Issued    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

CN    200980155596.X   

13-Dec-

2009Dec. 13,

2009

   200980155596.X    Issued    Dec.
2029
   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP


CN          201410413348.3   

20-Aug-

2014Aug. 20,

2014

   201410413348.3    Issued    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

EP    09832666.3   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

HK    15105678.1   

16-Jun-

2015June 16,

2015

   HK1205007    Issued    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

IN    2567/KOLNP/2011   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

KR    10-2011-7016270   

13-Dec-

2009Dec. 13,

2009

   10-1713346    Issued    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

US    15/016072   

04-Feb-

2016Feb. 4,

2016

   10383974    Issued    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

US    16/459778   

02-Jul-

2019July 2,

2019

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

GB    09832666.3   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

FR    09832666.3   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

DE    09832666.3   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

IT    09832666.3   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

CH    09832666.3   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

BE    09832666.3   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP

ES    09832666.3   

13-Dec-

2009Dec. 13,

2009

      Pending    Dec.

2029

   Directed to methods of making osteoinductive implants    OsteoampO

steoAMP


PT    09832666.3    13-Dec- 2009

Dec. 13, 2009

      Pending    Dec. 2029    Directed to methods of making osteoinductive implants    Osteoamp

OsteoAMP

US    09/925,193    09-Aug- 2001

Aug. 9, 2001

   7,429,248    Granted    July 2025    Directed to applying ultrasound to tissue using a modal converter having a plurality of angled sides    Exogen
AU    2006203281    01-Aug- 2006

Aug. 1, 2006

   2006203281    Granted    Aug. 2025    Directed to treating a neuropathy disease with ultrasound using a specific frequency and pulse rate for the signal    Exogen
US    11/462,271    03-Aug- 2006

Aug. 3, 2006

   8,048,006    Granted    Feb. 2029    Directed to treating a neuropathy disease with ultrasound using a specific frequency and pulse rate for the signal    Exogen
US    12/296,333    07-Apr- 2007

April 7, 2007

   8,226,582    Granted    June
2028
   Directed to applying ultrasound to tissue using a modal converter having an oblique angle and speed of sound similar to human tissue    Exogen
US    1017/779,638097,350    18-Feb- 2004

Nov. 13, 2020

   7,323,445    Granted

Pending

   Nov. 2040    Directed to placental tissue particulates composi-tions, methods of treating musculo- skeletal or orthopedic conditions, methods of treating pain associated with osteoarthritis, kits and methods of making the compositions    Exogen

MOTYS

US    11/809,383    01-Jun-2007    7,754,689    Granted          Exogen
USPCT    PCT/US2

0/60393

   Nov. 2113,

20192020

      Pending    Nov. 2040    Directed to placental tissue particulates compositions, for use in treating musculo- skeletal or orthopedic conditions, methods of treating pain associated with osteoarthritis, kits and methods of making the compositions    MOTYS